medRxiv

Individual-Level Counterfactual Analysis of SGLT2 Inhibitors Versus DPP4 Inhibitors in Diabetic Kidney Disease Using Causal Machine Learning

By Yuichiro Yano, Hajime Nagasu, Kanegae Hiroshi, Naoki Kashihara

Preprint: study in peopleInterventions

The paper

Yuichiro Yano, Hajime Nagasu, Kanegae Hiroshi, Naoki Kashihara

Juntendo University; Kawasaki Medical School

medRxiv, 3 Sep 2026, CC BY-NC-ND, Preprint, not peer-reviewed

doi.org/10.64898/2026.08.30.26361750

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk